New Study Shows Metformin Therapy May Reduce Risk of Colon Cancer in Diabetics, as Reported by DiabeticLive.com
A research team at the Shanghai Jiao Tong University in China has conducted a meta-analysis demonstrating that metformin treatment also appears to be associated with significantly lower risk of colorectal cancer in patients with type 2 diabetes as reported by DiabeticLive.com.
Orlando, FL (PRWEB) October 14, 2011
Metformin Therapy May Reduce Risk of Colon Cancer in Diabetics: If you have Type 2 diabetes, you should talk to your doctor about taking Metformin due to the lack of Cancer risk. Research has demonstrated that treatment with metformin is associated with significant decreases in the risk of the development of cancer cells, and with the development of cancer in general. Now a research team at the Shanghai Jiao Tong University in China has conducted a meta-analysis demonstrating that metformin treatment also appears to be associated with significantly lower risk of colorectal cancer in patients with type 2 diabetes.
Sign up for a free glucose meter at DiabeticLive.com.
“The results indicate that metformin therapy was associated with an estimated reduction of 37% in the risk of colorectal cancer among patients with type 2 diabetes,” wrote the researchers in the American Diabetes Association’s journal, “Diabetes Care.” The team was headed by Zhi-Jian Zhang, M.D., Ph.D., of the department of epidemiology and biostatistics at the School of Public Health.
Dr. Zhang and his colleagues pooled together data from previous research on the effects of metformin treatment on the development of colorectal cancer in patients with Type 2 diabetes using the PubMed and SciVerse Scopus databases. The team analyzed the research records and found five studies, consisting of 108,161 participants, which had been published from January 1966 to March 2011.
The research team performed its analysis and found that treatment with metformin was associated with a significant decrease in risk of developing colorectal neoplasm in patients with Type 2 diabetes compared to patients who did not receive metformin.
Dr. Zhang’s team did exclude one of the studies, which focused on colorectal adenoma; after the exclusion of that study, data from 107,961 patients remained. Of that number, 589 had developed colorectal cancer in the follow-up period of the studies. After analyzing the data from the four remaining studies, the team found that metformin still appeared to significantly reduce risk of colorectal cancer in patients with Type 2 diabetes.
The authors hypothesized that metformin’s cancer-suppression properties may be due to the role that it plays in the tumor suppression pathway: metformin is a component in the process that activates a gene called LKB1, which suppresses tumor growth. Metformin has also been shown in research to kill cancer stem cells and inhibit growth of colon carcinoma cells in rodents. Studies on non-diabetic humans have also shown promising results in metformin’s cancer-fighting qualities.
According to the authors, if further research determines that there is a causal link between metformin therapy and reduction in risk of colorectal cancer, it will likely be prescribed to most diabetics both as a method of controlling blood sugar and as a cancer prevention measure.
Get a free diabetic health insurance quote at DiabeticLive.com.
# # #
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/10/prweb8879551.htm